慢性硬膜下血腫に対する剥離可能コイル塞栓術 (SEED)
慢性硬膜下血腫に対するデタッチャブルコイル塞栓術の安全性と有効性
This is a prospective, multi-center, post market registry study designed to evaluate the safety and efficacy of treatment with Balt coils in patients with chronic subdural hematoma (cSDH).
調査の概要
詳細な説明
The primary objective of this observational registry study is to assess the safety and efficacy of Balt Coils as an adjunct to middle meningeal artery (MMA) embolization in a real-world setting among patients undergoing treatment for chronic subdural hematoma (cSDH), and explore correlations between patient characteristics, clinical characteristics, and outcomes. By collecting comprehensive, real-world data, the registry will characterize procedural inputs, document clinical and radiographic outcomes, and explore variation in technique and practice setting. The overarching goal is to generate a more complete understanding of Middle Meningeal Artery Embolization (MMAE) in diverse clinical environments, inform future prospective studies, and guide evidence-based adoption of this evolving therapy. Patients may be treated with Balt coils regardless of enrollment in the study as the decision to place the coils should be made independently as per standard of care and prior to enrollment in the study.
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Sukaina Davdani
- 電話番号:(212) 241-2524
- メール:Sukaina.Davdani@mountsinai.org
研究連絡先のバックアップ
- 名前:Sydney Edwards
- 電話番号:(212) 241-2524
- メール:Sydney.Edwards@mountsinai.org
研究場所
-
-
Arizona
-
Tucson、Arizona、アメリカ、85711
- まだ募集していません
- Carondelet Neurological Institute
-
主任研究者:
- Alexander Coon, MD
-
コンタクト:
- Matthew Pohlmeyer
- メール:Matthew.Pohlmeyer@tenethealth.org
-
-
California
-
San Deigo、California、アメリカ、92093
- まだ募集していません
- University of California - San Deigo
-
コンタクト:
- Pete Chase
- メール:PChase@Health.UCSD.edu
-
主任研究者:
- David Santiago-Dieppa, MD
-
Walnut Creek、California、アメリカ、94598
- 募集
- John Muir Health
-
主任研究者:
- Benjamin Yim, MD
-
コンタクト:
- Melenie Aaron
- メール:Melenie.Aaron@JohnMuirHealth.com
-
-
Kentucky
-
Louisville、Kentucky、アメリカ、40292
- まだ募集していません
- University of Louisville
-
コンタクト:
- Mechelle Kaufman
- メール:Mechelle.Kaufman@louisville.edu
-
主任研究者:
- Isaac Josh Abecassis, MD
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- まだ募集していません
- Oklahoma University Medical Center
-
主任研究者:
- Hakeem Shakir, MD
-
コンタクト:
- Michael Omimi
- メール:Michael-Omini@OU.edu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients with symptomatic chronic subdural hematoma (cSDH), with or without previous surgical evacuation that need additional treatment
説明
Inclusion criteria:
- Age ≥ 18
- Patients experiencing unilateral or bilateral non-acute subdural hematoma confirmed by CT imaging. Acute on Chronic or mixed density hematoma allowed.
- A clinical decision has been made to use coiling and/or embolics as treatment, with or without surgical debridement, independently as per standard of care and prior to enrollment in the study.
- Signed informed consent obtained by patient or Legal Authorized Representative (LAR)
Exclusion criteria:
- Primary acute SDH
- Prior MMAE in target territory
- Premorbid mRS > 3
- Common carotid stenosis >70% or prior carotid stent placement
- Significant medical contraindication to angiography (kidney failure/disease)
- Anatomical variations that would make MMA embolization difficult or unsafe
- Currently participating in an investigational (drug, device, etc.) clinical trial that may confound study endpoints
- Pregnancy
- Life expectancy ≤ 1 year
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:CASE_ONLY
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Participants with cSDH
All participants enrolled will be treated with the Balt coils.
|
MMA embolization utilizing Balt Coils
他の名前:
surgical or bedside evacuation pre or post-surgical debridement |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in hematoma volume
時間枠:180 days
|
Change in hematoma volume based on CT imaging |
180 days
|
|
Change in maximal thickness
時間枠:180 days
|
Change in maximal thickness based on CT imaging |
180 days
|
|
Change in midline shift
時間枠:180 days
|
Change in midline shift (mm) based on CT imaging |
180 days
|
|
Number of periprocedural major disabling stroke or any death
時間枠:30 days
|
Number of periprocedural major disabling stroke or any death |
30 days
|
|
Number of participants with symptomatic recurrence progression requiring retreatment
時間枠:180 days
|
Number of participants with symptomatic recurrence progression of the SDH requiring retreatment |
180 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Device-related adverse events (AE), serious adverse events (SAE), and procedural-related SAE
時間枠:180 days
|
Number of Adverse events and serious adverse events related to the device as assessed by an independent medical monitor |
180 days
|
|
Number of Acute successful embolization of the target vessel
時間枠:Immediately post-procedure
|
Determination of successful embolization based on angiographic imaging |
Immediately post-procedure
|
|
Change in EuroQoL 5 dimensions 5 levels (EQ-5D-5L)
時間枠:180 days
|
The EQ-5D is a generic instrument for describing and valuing health. The new version includes the 5 levels of severity in each of the existing five EQ-5D dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, and now called the EQ-5D-5L, each assessed on a 5-point scale (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems). Participants score each dimension based on their health that day and their responses are used to generate a health index score. Index scores could range from <0 (a health state equivalent to dead with negative values representing a state worse than dead) to 1 (full health). Lower scores indicate a higher QoL. |
180 days
|
協力者と研究者
捜査官
- 主任研究者:Christopher Kellner、Icahn School of Medicine at Mount Sinai
- 主任研究者:Benjamin Yim、John Muir Health
- 主任研究者:Alexander Coon、Carondelet Neurological Institute
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- STUDY-25-01365
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Upon the completion of the study, Mount Sinai's data management team will clean and analyze all data in preparation of manuscript writing and publication. Data that will be shared and published will be that of all participants combined to protect individual patient privacy and confidentiality.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。